EPS Creative Health Technology Group Ltd.
Established in 1999, our core business is to provide solutions for apparel supply chain management focused on knitwear to corporate clients in the U.S. and Japan.
In April 2021, we became a subsidiary of EPS Holdings, Inc, a Japan-based contract research organization (CRO), site management organization (SMO), and contract sales organization (CSO) for pharmaceutical and medical device development in Asia, and are newly engaged in healthcare business in China as well as other parts of Asia in cooperation with EPS Holdings, Inc.
Company Information
| Name | EPS Creative Health Technology Group Limited |
| Listed Exchange | HKEX（Stock Code：3860） |
| Incorporation Date | Nov 19, 2015 |
| Address | Room 3301, West Tower, Shun Tak Centre, Sheung Wan, Hong Kong |
| Principal Business | Apparel ODM business |
| Share Capital | HKD $5,221,774 |
| Parent Company | EPS Holding Ltd. (Japan) |
We provide one-stop apparel supply chain management solutions for its customers ranging from fashion trend analysis, product design and development, sourcing and procurement of materials, production management, quality control and logistics services.
Customers are mainly owners or sourcing agents of apparel retail brands based in Japan and the USA. We sale knitwear products such as pullovers, cardigans, vests and skirts with the provision of apparel supply chain management services to our customers.
As a trading company specializing in healthcare to connect Japan and China, we are working on the following businesses as a platform to support the commercialization of pharmaceuticals, medical devices, and health foods.
We are committed to promptly provide health care products such as beauty products and health foods to the targeted market, mainly from Japanese manufacturers, based on accurate understanding of the market needs. We will create a business platform for healthcare products connecting Japan with China and Southeast Asia, as a business development partner.
We promote the clinical development of promising medical seeds until they can be commercialized or license-out to partner companies, so as to promote new drugs to Japan and even to overseas markets centered in Asia.
